The impact of race on short term treatment response to bevacizumab in diabetic macular edema

The authors are commenting on the study entitled:“The impact of race on short term treatment response to bevacizumabin diabetic macular edema” published by Osathanugrahet al. in Am J Ophthalmology 2020; Doi: 10.1016/j.ajo.2020.09.042, which reported the impact of race and ethnicity on efficacy of intravitrealbevacizumab for diabetic macular edema in anti-vascular endothelial growth factor treatment naïve patients after one and three injections.The authors found that the race is a risk factor for treatment effect in diabetic macular edema. However, the validation, extrapolation, and generalizability of this finding can only be validated by statistical analyses including all the missing baseline potential risk factors referred to above by us in addition to the baseline characteristics already evaluated in this study, serving to emphasize the key metrics assessing the impact of race and ethnicity on efficacy of intravitrealbevacizumab for diabetic macular edema in anti-vascular endothelial growth factor treatment naïve patients.